NASDAQ:ECYT - Endocyte Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$14.29 -0.16 (-1.11 %)
(As of 05/21/2018 04:00 PM ET)
Previous Close$14.45
Today's Range$13.91 - $14.73
52-Week Range$1.17 - $14.86
Volume1.16 million shs
Average Volume1.87 million shs
Market Capitalization$1.00 billion
P/E Ratio-14.29
Dividend YieldN/A
Beta0.47

About Endocyte (NASDAQ:ECYT)

Endocyte logoEndocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The company's products in pre-clinical development include EC2629, a folate receptor-targeted SMDC for use in treating cancer; EC2319 for the treatment of inflammatory diseases; EC0371 for treating polycystic kidney disease; and SMDC bi-specific adaptor chimeric antigen receptor T-cell for the treatment of immunotherapy in cancer. Endocyte, Inc. has a collaboration agreement with Purdue Research Foundation; Master License Agreement with Purdue Research Foundation; Merck Sharp & Dohme Research GmbH; and Nihon Medi-Physic Co., LTD. The company was founded in 1995 and is headquartered in West Lafayette, Indiana.

Receive ECYT News and Ratings via Email

Sign-up to receive the latest news and ratings for ECYT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:ECYT
CUSIP29269A10
Phone765-463-7175

Debt

Debt-to-Equity RatioN/A
Current Ratio37.86
Quick Ratio37.86

Price-To-Earnings

Trailing P/E Ratio-14.29
Forward P/E Ratio-18.80
P/E GrowthN/A

Sales & Book Value

Annual Sales$70,000.00
Price / Sales14,187.93
Cash FlowN/A
Price / CashN/A
Book Value$1.99 per share
Price / Book7.18

Profitability

EPS (Most Recent Fiscal Year)($1.00)
Net Income$-55,060,000.00
Net Margins-70,510.81%
Return on Equity-34.20%
Return on Assets-32.76%

Miscellaneous

Employees44
Outstanding Shares69,500,000

Endocyte (NASDAQ:ECYT) Frequently Asked Questions

What is Endocyte's stock symbol?

Endocyte trades on the NASDAQ under the ticker symbol "ECYT."

How were Endocyte's earnings last quarter?

Endocyte (NASDAQ:ECYT) announced its quarterly earnings data on Wednesday, May, 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.03. The biopharmaceutical company had revenue of $0.02 million for the quarter. Endocyte had a negative net margin of 70,510.81% and a negative return on equity of 34.20%. View Endocyte's Earnings History.

What price target have analysts set for ECYT?

4 equities research analysts have issued 1-year price targets for Endocyte's shares. Their predictions range from $7.00 to $7.00. On average, they expect Endocyte's share price to reach $7.00 in the next twelve months. View Analyst Ratings for Endocyte.

Who are some of Endocyte's key competitors?

Who are Endocyte's key executives?

Endocyte's management team includes the folowing people:
  • Mr. Michael A. Sherman, CEO, Pres & Director (Age 52)
  • Dr. Philip S. Low, Co-Founder, Chief Science Officer & Director (Age 70)
  • Ms. Katherine K. Parker, VP of HR (Age 53)
  • Dr. Alison A. Armour, Chief Medical Officer (Age 54)
  • Dr. Christopher P. Leamon Ph.D., VP of R&D (Age 52)

Has Endocyte been receiving favorable news coverage?

News headlines about ECYT stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Endocyte earned a news sentiment score of 0.17 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 48.04 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Endocyte's major shareholders?

Endocyte's stock is owned by many different of institutional and retail investors. Top institutional shareholders include venBio Select Advisor LLC (8.19%), VHCP Management II LLC (6.19%), BlackRock Inc. (2.48%), Rock Springs Capital Management LP (0.97%), Eventide Asset Management LLC (0.50%) and Millennium Management LLC (0.27%). Company insiders that own Endocyte stock include Christopher P Leamon and Philip S Low. View Institutional Ownership Trends for Endocyte.

Which major investors are selling Endocyte stock?

ECYT stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and Barclays PLC. Company insiders that have sold Endocyte company stock in the last year include Christopher P Leamon and Philip S Low. View Insider Buying and Selling for Endocyte.

Which major investors are buying Endocyte stock?

ECYT stock was bought by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, VHCP Management II LLC, Rock Springs Capital Management LP, BlackRock Inc., Eventide Asset Management LLC, Tibra Equities Europe Ltd, Baird Financial Group Inc. and Element Capital Management LLC. View Insider Buying and Selling for Endocyte.

How do I buy shares of Endocyte?

Shares of ECYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Endocyte's stock price today?

One share of ECYT stock can currently be purchased for approximately $14.29.

How big of a company is Endocyte?

Endocyte has a market capitalization of $1.00 billion and generates $70,000.00 in revenue each year. The biopharmaceutical company earns $-55,060,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. Endocyte employs 44 workers across the globe.

How can I contact Endocyte?

Endocyte's mailing address is 3000 KENT AVENUE SUITE A1-100, WEST LAFAYETTE IN, 47906. The biopharmaceutical company can be reached via phone at 765-463-7175.


MarketBeat Community Rating for Endocyte (ECYT)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  250 (Vote Outperform)
Underperform Votes:  188 (Vote Underperform)
Total Votes:  438
MarketBeat's community ratings are surveys of what our community members think about Endocyte and other stocks. Vote "Outperform" if you believe ECYT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ECYT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Endocyte (NASDAQ:ECYT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Endocyte in the last 12 months. Their average twelve-month price target is $7.00, suggesting that the stock has a possible downside of 51.01%. The high price target for ECYT is $7.00 and the low price target for ECYT is $7.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.002.502.50
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.00$7.00$7.00$7.00
Price Target Upside: 51.01% downside26.70% downside92.84% upside92.84% upside

Endocyte (NASDAQ:ECYT) Consensus Price Target History

Price Target History for Endocyte (NASDAQ:ECYT)

Endocyte (NASDAQ:ECYT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/13/2018Jefferies GroupInitiated CoverageBuy ➝ BuyHighView Rating Details
3/9/2018Wells FargoInitiated CoverageOutperform ➝ OutperformHighView Rating Details
2/27/2018CowenUpgradeMarket Perform ➝ OutperformHighView Rating Details
10/3/2017WedbushUpgradeNeutral ➝ Outperform$2.00 ➝ $7.00HighView Rating Details
11/11/2016Credit Suisse GroupReiterated RatingBuy$7.00N/AView Rating Details
(Data available from 5/21/2016 forward)

Earnings

Endocyte (NASDAQ:ECYT) Earnings History and Estimates Chart

Earnings by Quarter for Endocyte (NASDAQ:ECYT)

Endocyte (NASDAQ:ECYT) Earnings Estimates

2018 EPS Consensus Estimate: ($0.71)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.17)($0.17)($0.17)
Q2 20181($0.15)($0.15)($0.15)
Q3 20181($0.18)($0.18)($0.18)
Q4 20181($0.21)($0.21)($0.21)

Endocyte (NASDAQ ECYT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018Q1 2018($0.19)($0.16)$0.02 millionViewN/AView Earnings Details
2/26/2018Q4 2017($0.16)($0.18)$0.01 millionViewListenView Earnings Details
11/6/2017Q3 2017($0.35)($0.55)$0.03 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.25)($0.28)$0.01 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.28)($0.27)$0.01 millionViewN/AView Earnings Details
3/10/2017Q4 2016($0.25)($0.26)$0.01 millionViewN/AView Earnings Details
11/9/2016Q316($0.27)($0.21)$0.03 millionViewListenView Earnings Details
8/4/2016Q2($0.26)($0.25)$0.01 millionViewN/AView Earnings Details
5/4/2016Q116($0.25)($0.24)$0.01 millionViewListenView Earnings Details
3/2/2016Q4($0.27)($0.23)$0.01 millionViewListenView Earnings Details
11/3/2015Q315($0.27)($0.24)$0.03 millionViewN/AView Earnings Details
8/4/2015Q215($0.30)($0.25)$0.01 millionViewN/AView Earnings Details
5/7/2015Q115($0.24)($0.26)$0.01 millionViewN/AView Earnings Details
3/2/2015Q414($0.24)($0.19)$2.55 million$12.00 millionViewN/AView Earnings Details
11/5/2014Q314($0.21)($0.14)$5.10 million$3.90 millionViewN/AView Earnings Details
7/29/2014Q214$0.11$0.52$26.62 million$49.17 millionViewN/AView Earnings Details
5/2/2014Q114($0.15)($0.09)$15.07 million$17.30 millionViewN/AView Earnings Details
2/24/2014Q413($0.14)($0.08)$15.90 million$17.30 millionViewN/AView Earnings Details
11/5/2013Q3 2013($0.19)($0.08)$15.89 million$16.60 millionViewN/AView Earnings Details
8/1/2013Q2 2013($0.08)($0.10)$15.34 million$16.48 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.06)($0.11)$14.24 million$14.50 millionViewN/AView Earnings Details
4/15/2013Q413($0.10)$8.50 million$13.60 millionViewN/AView Earnings Details
2/25/2013Q4 2012($0.02)($0.02)ViewN/AView Earnings Details
11/1/2012Q3 2012$0.01($0.03)ViewN/AView Earnings Details
8/2/2012Q2 2012$0.39($0.12)ViewN/AView Earnings Details
5/10/2012Q1 2012($0.31)($0.27)ViewN/AView Earnings Details
3/13/2012Q4 2011($0.34)($0.30)ViewN/AView Earnings Details
11/10/2011Q3 2011($0.33)($0.36)ViewN/AView Earnings Details
8/11/2011Q2 2011($0.27)($0.35)ViewN/AView Earnings Details
5/5/2011Q1 2011($0.40)($0.43)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Endocyte (NASDAQ:ECYT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Endocyte (NASDAQ ECYT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.65%
Institutional Ownership Percentage: 64.51%
Insider Trading History for Endocyte (NASDAQ:ECYT)
Insider Trading History for Endocyte (NASDAQ:ECYT)

Endocyte (NASDAQ ECYT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/9/2018Christopher P LeamonVPSell5,036$9.07$45,676.52143,470View SEC Filing  
12/28/2017Philip S LowInsiderSell50,511$4.41$222,753.51View SEC Filing  
12/28/2017Philip S LowInsiderSell50,511$4.41$222,753.51354,050View SEC Filing  
12/1/2017Christopher P LeamonVPSell23,231$5.04$117,084.24150,579View SEC Filing  
11/13/2017Philip S LowInsiderBuy5,600$4.84$27,104.00283,005View SEC Filing  
12/30/2016Christopher P. LeamonVPSell23,244$2.55$59,272.20View SEC Filing  
5/10/2016Philip S LowInsiderBuy11,375$3.52$40,040.00206,606View SEC Filing  
1/19/2016Fred A. MiddletonDirectorBuy10,000$2.79$27,900.00200,999View SEC Filing  
1/15/2016Fred A. MiddletonDirectorBuy20,000$2.80$56,000.00200,999View SEC Filing  
4/9/2014Allen RitterVPSell1,000$21.16$21,160.0034,282View SEC Filing  
3/21/2014Allen RitterVPSell8,000$33.11$264,880.0012,722View SEC Filing  
2/14/2014Philip LowInsiderSell6,000$15.00$90,000.00200,819View SEC Filing  
12/2/2013P Ron EllisCEOSell3,000$12.00$36,000.0029,154View SEC Filing  
9/16/2013Allen RitterVPSell2,000$17.06$34,120.0015,722View SEC Filing  
9/12/2013David MeekInsiderSell10,000$15.50$155,000.00View SEC Filing  
9/3/2013P Ron EllisCEOSell3,000$14.54$43,620.0029,154View SEC Filing  
8/30/2013Allen RitterVPSell6,000$14.36$86,160.0017,722View SEC Filing  
8/6/2013Chandra LovejoyVPSell7,000$17.29$121,030.00View SEC Filing  
8/1/2013P Ron EllisCEOSell3,000$18.12$54,360.0029,154View SEC Filing  
7/15/2013P Ron EllisCEOSell3,000$17.01$51,030.00View SEC Filing  
5/28/2013Ann HanhamDirectorSell9,900$14.10$139,590.00View SEC Filing  
5/22/2013Ann HanhamDirectorSell40,000$14.38$575,200.00View SEC Filing  
5/17/2013Ann HanhamDirectorSell37,200$14.41$536,052.00View SEC Filing  
5/17/2013Binh NguyenVPSell17,300$14.42$249,466.00View SEC Filing  
5/15/2013Ann HanhamDirectorSell40,200$14.69$590,538.00View SEC Filing  
5/14/2013Christopher P LeamonVPSell5,000$14.70$73,500.00View SEC Filing  
2/25/2013Chandra D LovejoyVPSell2,102$9.70$20,389.40View SEC Filing  
12/26/2012Chandra D LovejoyVPSell2,209$9.05$19,991.45View SEC Filing  
11/26/2012Chandra D LovejoyVPSell2,209$8.72$19,262.48View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Endocyte (NASDAQ ECYT) News Headlines

Source:
DateHeadline
Should You Be Concerned With Endocyte Inc’s (NASDAQ:ECYT) -15.38% Earnings Drop?Should You Be Concerned With Endocyte Inc’s (NASDAQ:ECYT) -15.38% Earnings Drop?
finance.yahoo.com - May 17 at 4:02 PM
Why Endocyte Stock Jumped Higher TodayWhy Endocyte Stock Jumped Higher Today
www.fool.com - May 17 at 1:40 PM
Endocytes radiotherapeutic 177Lu-PSMA-617 shows positive effect in mid-stage prostate cancer study; shares ahead ...Endocyte's radiotherapeutic 177Lu-PSMA-617 shows positive effect in mid-stage prostate cancer study; shares ahead ...
seekingalpha.com - May 17 at 10:02 AM
Endocyte Announces Presentation of Phase 2 Data from Investigator-Initiated Prostate Cancer Trial of 177Lu-PSMA ...Endocyte Announces Presentation of Phase 2 Data from Investigator-Initiated Prostate Cancer Trial of 177Lu-PSMA ...
globenewswire.com - May 17 at 10:02 AM
Endocyte Announces Presentation of Phase 2 Data from Investigator-Initiated Prostate Cancer Trial of 177Lu-PSMA-617 at the 2018 American Society of Clinical Oncology (ASCO) Annual MeetingEndocyte Announces Presentation of Phase 2 Data from Investigator-Initiated Prostate Cancer Trial of 177Lu-PSMA-617 at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - May 17 at 10:02 AM
Endocyte (ECYT) Forecasted to Earn FY2022 Earnings of $0.91 Per ShareEndocyte (ECYT) Forecasted to Earn FY2022 Earnings of $0.91 Per Share
www.americanbankingnews.com - May 14 at 5:05 AM
Wedbush Weighs in on Endocytes Q2 2018 Earnings (ECYT)Wedbush Weighs in on Endocyte's Q2 2018 Earnings (ECYT)
www.americanbankingnews.com - May 14 at 2:33 AM
Endocyte (ECYT) Downgraded to Hold at Zacks Investment ResearchEndocyte (ECYT) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - May 11 at 7:05 PM
Endocyte (ECYT) Releases  Earnings Results, Beats Estimates By $0.03 EPSEndocyte (ECYT) Releases Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - May 10 at 11:50 PM
Edited Transcript of ECYT earnings conference call or presentation 9-May-18 12:30pm GMTEdited Transcript of ECYT earnings conference call or presentation 9-May-18 12:30pm GMT
finance.yahoo.com - May 10 at 10:06 AM
Form 10-Q ENDOCYTE INC For: Mar 31Form 10-Q ENDOCYTE INC For: Mar 31
www.streetinsider.com - May 9 at 4:10 PM
BRIEF-Endocyte Reports Q1 Loss Per Share $0.16BRIEF-Endocyte Reports Q1 Loss Per Share $0.16
www.reuters.com - May 9 at 4:10 PM
Endocytes (ECYT) CEO Mike Sherman on Q1 2018 Results - Earnings Call TranscriptEndocyte's (ECYT) CEO Mike Sherman on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 4:10 PM
Endocyte (ECYT) Posts Narrower than Expected Loss in Q1Endocyte (ECYT) Posts Narrower than Expected Loss in Q1
finance.yahoo.com - May 9 at 4:10 PM
Endocyte Q1 revenues up 33%; shares ahead 2% premarketEndocyte Q1 revenues up 33%; shares ahead 2% premarket
seekingalpha.com - May 9 at 9:55 AM
Endocyte Announces The Lancet Oncology Publication of Phase 2 Data From Investigator-Initiated Prostate Cancer ...Endocyte Announces The Lancet Oncology Publication of Phase 2 Data From Investigator-Initiated Prostate Cancer ...
www.globenewswire.com - May 9 at 9:55 AM
Endocyte, Inc. 2018 Q1 - Results - Earnings Call SlidesEndocyte, Inc. 2018 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 9 at 9:55 AM
Endocyte: 1Q Earnings SnapshotEndocyte: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 9:55 AM
Endocyte Announces The Lancet Oncology Publication of Phase 2 Data From Investigator-Initiated Prostate Cancer Trial of (177)Lu-PSMA-617Endocyte Announces The Lancet Oncology Publication of Phase 2 Data From Investigator-Initiated Prostate Cancer Trial of (177)Lu-PSMA-617
finance.yahoo.com - May 9 at 9:55 AM
Investors Buy Large Volume of Endocyte Put Options (ECYT)Investors Buy Large Volume of Endocyte Put Options (ECYT)
www.americanbankingnews.com - May 9 at 6:38 AM
Loss-Making Endocyte Inc (NASDAQ:ECYT) Expected To BreakevenLoss-Making Endocyte Inc (NASDAQ:ECYT) Expected To Breakeven
finance.yahoo.com - May 7 at 4:10 PM
-$0.19 Earnings Per Share Expected for Endocyte (ECYT) This Quarter-$0.19 Earnings Per Share Expected for Endocyte (ECYT) This Quarter
www.americanbankingnews.com - May 5 at 9:32 AM
Endocyte (ECYT) Stock Rating Upgraded by BidaskClubEndocyte (ECYT) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - May 5 at 12:19 AM
Endocyte (ECYT) Upgraded to Strong-Buy by ValuEngineEndocyte (ECYT) Upgraded to Strong-Buy by ValuEngine
www.americanbankingnews.com - May 3 at 10:55 PM
Endocyte to Present at Deutsche Banks 43rd Annual Health Care ConferenceEndocyte to Present at Deutsche Bank's 43rd Annual Health Care Conference
globenewswire.com - May 2 at 9:50 AM
Endocyte (ECYT) Upgraded by Zacks Investment Research to "Buy"Endocyte (ECYT) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - May 1 at 12:26 PM
Endocyte (ECYT) to Release Quarterly Earnings on MondayEndocyte (ECYT) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - April 30 at 11:56 AM
Endocyte (ECYT) Given Consensus Recommendation of "Buy" by BrokeragesEndocyte (ECYT) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 28 at 3:37 AM
Endocyte (ECYT) Rating Lowered to Buy at BidaskClubEndocyte (ECYT) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - April 26 at 1:31 PM
New Research: Key Drivers of Growth for OFG, Oshkosh, Vishay Precision Group, Endocyte, BioCryst Pharmaceuticals ...New Research: Key Drivers of Growth for OFG, Oshkosh, Vishay Precision Group, Endocyte, BioCryst Pharmaceuticals ...
www.nasdaq.com - April 26 at 9:54 AM
Endocyte (ECYT) Expected to Post Earnings of -$0.19 Per ShareEndocyte (ECYT) Expected to Post Earnings of -$0.19 Per Share
www.americanbankingnews.com - April 18 at 9:31 AM
Wedbush Equities Analysts Boost Earnings Estimates for Endocyte (ECYT)Wedbush Equities Analysts Boost Earnings Estimates for Endocyte (ECYT)
www.americanbankingnews.com - April 18 at 7:58 AM
BRIEF-Endocyte Says Data Presented At AACR Show That EC17 Penetrates Solid Tumors Within Minutes And Is ...BRIEF-Endocyte Says Data Presented At AACR Show That EC17 Penetrates Solid Tumors Within Minutes And Is ...
www.reuters.com - April 16 at 9:56 AM
Endocyte Presents Data from its CAR T Platform at American Association for Cancer Research (AACR) Annual Meeting ...Endocyte Presents Data from its CAR T Platform at American Association for Cancer Research (AACR) Annual Meeting ...
globenewswire.com - April 16 at 9:56 AM
Endocyte Presents Data from its CAR T Platform at American Association for Cancer Research (AACR) Annual Meeting 2018Endocyte Presents Data from its CAR T Platform at American Association for Cancer Research (AACR) Annual Meeting 2018
finance.yahoo.com - April 16 at 9:56 AM
Endocyte (ECYT) Earns Buy Rating from Analysts at Jefferies GroupEndocyte (ECYT) Earns Buy Rating from Analysts at Jefferies Group
www.americanbankingnews.com - April 13 at 10:37 AM
Endocyte Inc. (ECYT) Is Approaching The Highs Of The YearEndocyte Inc. (ECYT) Is Approaching The Highs Of The Year
www.nasdaq.com - April 13 at 10:16 AM
Endocyte (ECYT) Upgraded by ValuEngine to SellEndocyte (ECYT) Upgraded by ValuEngine to Sell
www.americanbankingnews.com - April 8 at 12:54 PM
Endocyte (ECYT) Receives "Hold" Rating from CowenEndocyte (ECYT) Receives "Hold" Rating from Cowen
www.americanbankingnews.com - April 8 at 10:49 AM
New Analyst Coverage Puts Spotlight on 5 StocksNew Analyst Coverage Puts Spotlight on 5 Stocks
finance.yahoo.com - April 4 at 5:24 PM
Endocyte (ECYT) Upgraded to "Buy" at ValuEngineEndocyte (ECYT) Upgraded to "Buy" at ValuEngine
www.americanbankingnews.com - April 3 at 4:48 PM
Endocyte, Inc. (ECYT) Given Consensus Rating of "Buy" by AnalystsEndocyte, Inc. (ECYT) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - April 3 at 3:08 AM
 Brokerages Expect Endocyte, Inc. (ECYT) Will Post Earnings of -$0.18 Per Share Brokerages Expect Endocyte, Inc. (ECYT) Will Post Earnings of -$0.18 Per Share
www.americanbankingnews.com - April 1 at 7:23 AM
Endocyte (ECYT) Rating Increased to Hold at Zacks Investment ResearchEndocyte (ECYT) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - March 31 at 6:04 PM
Endocyte, Inc. (ECYT) Short Interest Up 131.5% in MarchEndocyte, Inc. (ECYT) Short Interest Up 131.5% in March
www.americanbankingnews.com - March 28 at 2:44 AM
Endocyte (ECYT) Upgraded by Cowen to "Outperform"Endocyte (ECYT) Upgraded by Cowen to "Outperform"
www.americanbankingnews.com - March 24 at 10:39 PM
Head to Head Survey: Mateon Therapeutics (MATN) vs. Endocyte (ECYT)Head to Head Survey: Mateon Therapeutics (MATN) vs. Endocyte (ECYT)
www.americanbankingnews.com - March 21 at 11:25 AM
BRIEF-Endocyte Nominates Dawn Svoronos For Election To Its BoardBRIEF-Endocyte Nominates Dawn Svoronos For Election To Its Board
www.reuters.com - March 16 at 10:58 AM
Endocyte Announces Presentations at American Association for Cancer Research (AACR) Annual Meeting 2018Endocyte Announces Presentations at American Association for Cancer Research (AACR) Annual Meeting 2018
finance.yahoo.com - March 15 at 4:09 PM
 Brokerages Expect Endocyte, Inc. (ECYT) to Post -$0.18 Earnings Per Share Brokerages Expect Endocyte, Inc. (ECYT) to Post -$0.18 Earnings Per Share
www.americanbankingnews.com - March 15 at 5:18 AM

SEC Filings

Endocyte (NASDAQ:ECYT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Endocyte (NASDAQ:ECYT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Endocyte (NASDAQ ECYT) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.